Human Genomics (May 2024)

Development, validation and application of single molecule molecular inversion probe based novel integrated genetic screening method for 29 common lysosomal storage disorders in India

  • Harsh Sheth,
  • Aadhira Nair,
  • Riddhi Bhavsar,
  • Mahesh Kamate,
  • Vykuntaraju K. Gowda,
  • Ashish Bavdekar,
  • Sandeep Kadam,
  • Sheela Nampoothiri,
  • Inusha Panigrahi,
  • Anupriya Kaur,
  • Siddharth Shah,
  • Sanjeev Mehta,
  • Sujatha Jagadeesan,
  • Indrani Suresh,
  • Seema Kapoor,
  • Shruti Bajaj,
  • Radha Rama Devi,
  • Ashka Prajapati,
  • Koumudi Godbole,
  • Harsh Patel,
  • Zulfiqar Luhar,
  • Raju C. Shah,
  • Anand Iyer,
  • Sunita Bijarnia,
  • Ratna Puri,
  • Mamta Muranjan,
  • Ami Shah,
  • Suvarna Magar,
  • Neerja Gupta,
  • Naresh Tayade,
  • Ajit Gandhi,
  • Ajit Sowani,
  • Shrutikaa Kale,
  • Anil Jalan,
  • Dhaval Solanki,
  • Ashwin Dalal,
  • Shrikant Mane,
  • C. Ratna Prabha,
  • Frenny Sheth,
  • Chaitanya G. Joshi,
  • Madhvi Joshi,
  • Jayesh Sheth

DOI
https://doi.org/10.1186/s40246-024-00613-9
Journal volume & issue
Vol. 18, no. 1
pp. 1 – 20

Abstract

Read online

Abstract Background Current clinical diagnosis pathway for lysosomal storage disorders (LSDs) involves sequential biochemical enzymatic tests followed by DNA sequencing, which is iterative, has low diagnostic yield and is costly due to overlapping clinical presentations. Here, we describe a novel low-cost and high-throughput sequencing assay using single-molecule molecular inversion probes (smMIPs) to screen for causative single nucleotide variants (SNVs) and copy number variants (CNVs) in genes associated with 29 common LSDs in India. Results 903 smMIPs were designed to target exon and exon–intron boundaries of targeted genes (n = 23; 53.7 kb of the human genome) and were equimolarly pooled to create a sequencing library. After extensive validation in a cohort of 50 patients, we screened 300 patients with either biochemical diagnosis (n = 187) or clinical suspicion (n = 113) of LSDs. A diagnostic yield of 83.4% was observed in patients with prior biochemical diagnosis of LSD. Furthermore, diagnostic yield of 73.9% (n = 54/73) was observed in patients with high clinical suspicion of LSD in contrast with 2.4% (n = 1/40) in patients with low clinical suspicion of LSD. In addition to detecting SNVs, the assay could detect single and multi-exon copy number variants with high confidence. Critically, Niemann-Pick disease type C and neuronal ceroid lipofuscinosis-6 diseases for which biochemical testing is unavailable, could be diagnosed using our assay. Lastly, we observed a non-inferior performance of the assay in DNA extracted from dried blood spots in comparison with whole blood. Conclusion We developed a flexible and scalable assay to reliably detect genetic causes of 29 common LSDs in India. The assay consolidates the detection of multiple variant types in multiple sample types while having improved diagnostic yield at same or lower cost compared to current clinical paradigm.

Keywords